Thu, Dec 25, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Alternative Market Briefing

BlueCrest’ systematic trend following hedge fund loses almost 17% in six weeks - Reuters

Friday, July 05, 2013

Benedicte Gravrand, Opalesque Geneva:

The BlueTrend fund, one of BlueCrest Capital Management’s systematic trend-following hedge funds, has recently had one of its worst ever peak-to-trough losses, writes Laurence Fletcher of Reuters. He adds that a listed feeder fund that channels capital into the $16 billion BlueTrend fund has indeed lost 16.9% between May 17 and June 28. The Feeder replicates the performance of the flagship fund. This equates to a loss of around $2.7bn in the main fund, which has never had a losing calendar year since its 2004 launch.

According to Trustnet.com, BlueCrest’s BlueTrend fund (USD class)’s estimated NAV of the fund’s ordinary share was $0.89 as of 28th June.

Bloomberg reported last week that the $14 billion hedge fund BlueTrend had lost 8.3% in June (and -9.2% in 2013). The fund produced an average annual return of 12.9% since its inception in 2004.

Systematic funds did not fare well in May either. The Barclay CTA Index went down 1.31% in May (+0.61% YTD). "May’s tren......................

To view our full article Click here

Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Hong Kong-Shanghai stock link fails to live up to expectation so far[more]

    Komfie Manalo, Opalesque Asia: In a report, Reuters said that demand has been subdued with the bulk of activities coming from short-term speculative investors. Las

  2. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  3. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  4. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for

  5. CFTC Revokes Registrations of Illinois Resident Aleks A. Kins and Chicago-based AlphaMetrix, LLC[more]

    Matthias Knab, Opalesque: The U.S. Commodity Futures Trading Commission (CFTC) today announced that it has revoked the registration of Aleks A. Kins of Chicago, Illinois, as an Associated Person and the registrations of AlphaMetrix, LLC (AlphaMetrix), a Delaware limited liability company with its